ScreenerHero

XNCR Xencor, Inc.

NAS · US · Healthcare · Biotechnology · xencor.com
24.26USD-0.41%Mkt Cap: 1.80B $P/E: —

Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of engineered antibodies for the treatment of cancer and autoimmune diseases. The company provides Ultomiris to treat pat…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap1.80B USD
Enterprise Value1.52B USD
Revenue (TTM)104.97M USD
Gross Profit-150.79M USD
Net Income (TTM)-91.92M USD
Revenue/Share1.40 USD
Last Price24.26 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees260
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-6.85
PEG—
EV/EBITDA-7.41
EV/Revenue14.53
P/S17.25
P/B3.60
EPS (TTM)-2.16
EPS (Forward)-3.56
52W Range
10.2473% of range29.37
52W High29.37 USD
52W Low10.24 USD
Profitability
Gross Margin-143.65%
Oper. Margin-72.37%
EBITDA Margin-196.15%
Profit Margin-73.20%
ROE-14.46%
ROA-10.50%
Growth
Revenue Growth17.50%
Earnings Growth—
Cash Flow & Leverage
Operating CF-135.12M USD
CapEx (TTM)3.15M USD
FCF Margin-90.06%
FCF Yield-5.24%
Net Debt-286.34M USD
Net Debt/EBITDA1.39
Balance Sheet
Debt/Equity0.30
Current Ratio6.39
Quick Ratio6.09
Book Value/Sh6.77 USD
Cash/Share6.14 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.5 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)31.42 USD
Upside (mean)+29.5%
Target Range20.00 USD – 46.00 USD
20.00+29.5% to mean46.00
# Analysts12
Ownership
Shares Out.74.35M
Float54.25M
Insiders1.22%
Institutions114.50%
Short Interest
Short Ratio11.2d
Short % Float30.05%
Short % Out.21.18%
Shares Short15.75M
Short (prev mo.)14.19M
Technical
SMA 5024.30 (-0.2%)
SMA 20015.93 (+52.3%)
Beta0.90
S&P 52W Chg16.45%
Avg Vol (30d)1.39M
Avg Vol (10d)1.27M
Technical Indicators
RSI (14)49.2
MACD0.3154
MACD Signal0.5249
MACD Hist.-0.2095
BB Upper26.15 USD
BB Middle24.75 USD
BB Lower23.35 USD
BB Width11.31%
ATR (14)1.357 USD
Vol Ratio (20d)1.21x